Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy | Zendy

Willemijn AKM Windt | Zendy; Atsua Tahara | Zendy; Alex C.A. Kluppel | Zendy; Dick de Zeeuw | Zendy; Robert H. Henning | Zendy; Richard PE van Dokkum | Zendy

Open Access

Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy

Author(s) -

Willemijn AKM Windt,

Atsua Tahara,

Alex C.A. Kluppel,

Dick de Zeeuw,

Robert H. Henning,

Richard PE van Dokkum

Publication year - 2006

Publication title -

journal of the renin-angiotensin-aldosterone system

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.457

H-Index - 46

eISSN - 1752-8976

pISSN - 1470-3203

DOI - 10.3317/jraas.2006.041

Subject(s) - glomerulosclerosis , medicine , focal segmental glomerulosclerosis , proteinuria , nephrectomy , urology , endocrinology , antagonist , vasopressin receptor , kidney , receptor

Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure. To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research